IDEXX Laboratories shares closed at $553.66 on Wednesday, marking their second straight day of losses and finishing 28.09% below the 52-week high reached in November.
The company's stock underperformed major competitors, with Johnson & Johnson, Medtronic, and Boston Scientific also declining but to a lesser extent or similar levels.
Trading volume for IDEXX exceeded its 50-day average, reflecting heightened investor activity during a generally negative session for the S&P 500 and Dow Jones Industrial Average.
With insiders selling millions in stock, what do they know about IDEXX's future?
Can IDEXX's new diagnostic technology overcome the industry-wide slump in vet visits?
As competitors falter, is the entire animal health sector facing a prolonged downturn?
Is the 28% stock drop a major buying opportunity or a serious warning sign?
How will the new CEO navigate declining clinic traffic to meet ambitious growth targets?